KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Total Non-Current Liabilities: 2020-2024

Historic Total Non-Current Liabilities for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $227.9 million.

  • AbCellera Biologics' Total Non-Current Liabilities rose 37.41% to $323.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $323.1 million, marking a year-over-year increase of 37.41%. This contributed to the annual value of $227.9 million for FY2024, which is 5.12% up from last year.
  • According to the latest figures from FY2024, AbCellera Biologics' Total Non-Current Liabilities is $227.9 million, which was up 5.12% from $216.8 million recorded in FY2023.
  • AbCellera Biologics' Total Non-Current Liabilities' 5-year high stood at $227.9 million during FY2024, with a 5-year trough of $71.5 million in FY2020.
  • In the last 3 years, AbCellera Biologics' Total Non-Current Liabilities had a median value of $216.8 million in 2023 and averaged $211.3 million.
  • Data for AbCellera Biologics' Total Non-Current Liabilities shows a peak YoY surged of 140.66% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows AbCellera Biologics' Total Non-Current Liabilities stood at $71.5 million in 2020, then surged by 140.66% to $172.2 million in 2021, then climbed by 9.96% to $189.3 million in 2022, then increased by 14.50% to $216.8 million in 2023, then climbed by 5.12% to $227.9 million in 2024.